이 기사의 번역을 준비하고 있습니다. 그동안 영어 원문을 임시로 표시합니다.
비즈니스 · 2025. 7. 2.1 분 읽기
Determination of Regulatory Review Period for Purposes of Patent Extension; ELREXFIO; Correction
로컬 자동 번역 · 원본 출처 언어
요약
The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on May 12, 2025. The document, entitled "Determination of Regulatory Review Period for Purposes of Patent Extension; ELREXFIO," announced the determination of the regulatory review period for ELREXFIO (elranatamab-bcmm) for purposes of patent extension. The document was published with only one of two docket numbers. This document corrects that error.
원본 출처 언어: Federal Register — Food and Drug Administration원문 발표 열기 →